NOX66 | THE "NEW" PROSTATE CANCER INFOLINK

Follow The "New" Prostate Cancer InfoLink news blog on TWITTER or FACEBOOK.
The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
A service of

Prostate Cancer International.
Awards
Other PCI web sites

El Cáncer de Próstata Latinoamérica
Prostate Cancer Africa
Prostate Cancer Caribbean
Solidarité Prostate InfoLink
Copyright © 2008-18 Prostate Cancer International, Inc.

Early data from the LuPIN trial in men with mCRPC

Posted on July 16, 2019 by Sitemaster

A lot of people are hopeful that treatment with a new form of targeted nuclear radiation therapy — lutetium-177 PSMA 617 (¹⁷⁷Lu PSMA) — will be able to significantly extend survival of men with metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, NOX66, PSMA | 1 Comment »

THE "NEW" PROSTATE CANCER INFOLINK

A service of

Awards

Other PCI web sites

Early data from the LuPIN trial in men with mCRPC

Disclaimer

Hot Posts …

… and Archives